News | August 04, 2023
Dabur India posts Q1 FY24 PAT at Rs. 463.88 Cr
The company has posted net profit of Rs. 463.88 crores for the period ended June 30, 2023
The company has posted net profit of Rs. 463.88 crores for the period ended June 30, 2023
The company has reported total income of Rs. 4836.89 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1787.16 crores during the period ended June 30, 2023
The company has reported total income of Rs. 62.15 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1248.51 crores during the period ended June 30, 2023
The company has reported total income of Rs. 135.87 crores during the period ended June 30, 2023
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices
Subscribe To Our Newsletter & Stay Updated
